- Home
- MHUA vs BCDA Comparison
MHUA vs BCDA Comparison
Compare MHUA & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- BCDA
- Stock Information
- Founded
- MHUA 1990
- BCDA N/A
- Country
- MHUA China
- BCDA United States
- Employees
- MHUA N/A
- BCDA N/A
- Industry
- MHUA Medical Specialities
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- BCDA Health Care
- Exchange
- MHUA Nasdaq
- BCDA Nasdaq
- Market Cap
- MHUA 11.8M
- BCDA 11.3M
- IPO Year
- MHUA 2022
- BCDA N/A
- Fundamental
- Price
- MHUA $0.46
- BCDA $2.16
- Analyst Decision
- MHUA
- BCDA Strong Buy
- Analyst Count
- MHUA 0
- BCDA 1
- Target Price
- MHUA N/A
- BCDA $25.00
- AVG Volume (30 Days)
- MHUA 132.7K
- BCDA 45.6K
- Earning Date
- MHUA 09-19-2025
- BCDA 11-12-2025
- Dividend Yield
- MHUA N/A
- BCDA N/A
- EPS Growth
- MHUA N/A
- BCDA N/A
- EPS
- MHUA 0.40
- BCDA N/A
- Revenue
- MHUA $96,909,642.00
- BCDA N/A
- Revenue This Year
- MHUA N/A
- BCDA N/A
- Revenue Next Year
- MHUA N/A
- BCDA N/A
- P/E Ratio
- MHUA $1.07
- BCDA N/A
- Revenue Growth
- MHUA N/A
- BCDA N/A
- 52 Week Low
- MHUA $0.25
- BCDA $1.63
- 52 Week High
- MHUA $1.24
- BCDA $3.26
- Technical
- Relative Strength Index (RSI)
- MHUA 65.24
- BCDA 59.44
- Support Level
- MHUA $0.35
- BCDA $1.90
- Resistance Level
- MHUA $0.46
- BCDA $2.29
- Average True Range (ATR)
- MHUA 0.04
- BCDA 0.09
- MACD
- MHUA 0.00
- BCDA 0.04
- Stochastic Oscillator
- MHUA 73.33
- BCDA 66.67
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).